Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dynamics of ABL Mutations in Imatinib Failed Ph Positive or Bcr-Abl Positive CML CP or AP Patients Who Treated With Nilotinib as Second-line TKI Therapy (AMICAN-Prospective)in Asia

NCT01562847 is registered in ClinicalTrials.gov with Seoul St. Mary's Hospital as lead sponsor.

NCT NCT01562847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01562847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dynamics of ABL Mutations in Imatinib Failed Ph Positive or Bcr-Abl Positive CML CP or AP Patients Who Treated With Nilotinib as Second-line TKI Therapy (AMICAN-Prospective)in Asia
Lead sponsor
Seoul St. Mary's Hospital
Phase
Observational
Overall status
Unknown status
Start date
July 31, 2011
Completion date
June 30, 2015
Enrollment
125 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia